7results about How to "Maintain steady state" patented technology

The invention discloses bifidobacterium longum subsp. Infantis i18 with an effect of regulating intestinal flora and application of the bifidobacterium longum subsp. Infantis i18, and belongs to the technical field of microbial engineering. The bifidobacterium longum subsp. Infantis i18 strain is preserved in the China General Microbiological Culture Collection Center, the preservation address is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, the preservation date is July 25, 2024, the preservation number is CGMCC NO.31411, and the Latin name is Bifidobacterium longum subsp. Infantis. The invention also discloses a preparation method of the bifidobacterium longum subsp. Infantis strain. The bifidobacterium longum subsp. Infantis i18 provided by the invention has a bidirectional regulation effect, can relax bowel, relieve diarrhea, maintain intestinal steady state and regulate intestinal flora at the same time, expands the application range of the bifidobacterium longum subsp. Infantis, and enriches the types of the domestic bifidobacterium longum subsp. Infantis. The preparation method is suitable for preparing the probiotic agent or the infant formula milk powder.

The application discloses a DNA sulfur-modified bacillus subtilis and application thereof in alleviating alcoholic diseases, and relates to the field of biochemistry.The application provides a DNA sulfur-modified bacillus subtilis, which is named as Bacillus subtilis E10-1 and has a preservation number of CCTCC NO: M20253036.It is verified through animal experiments that the DNA sulfur-modified bacillus subtilis E10-1 is more resistant to alcohol than a strain in which sulfur modification is knocked out, can reduce the levels of indexes such as glutathione pyrotransaminase, glutathione transaminase and urea nitrogen in serum of a host after drinking alcohol, and the level of interferon gamma, can increase the levels of total protein, superoxide dismutase and glutathione peroxidase, can alleviate oxidative stress damage caused by alcohol, can reduce inflammatory reactions of various organ tissues, can maintain normal physiological functions of cells, can repair intestinal barriers, and can maintain intestinal flora homeostasis, so that alcoholic related diseases can be prevented and / or treated.

This invention belongs to the field of microbial technology, specifically relating to a strain of *Lactobacillus vaginalis* 244 and its applications. The *Lactobacillus vaginalis* described in this invention... Limosilactobacillus vaginal Lactobacillus vaginis 244 was deposited at the Guangdong Provincial Center for Microbial Culture Collection on May 22, 2026, with accession number GDMCC No: 68333. Lactobacillus vaginis 244 exhibits good antibacterial, stress-resistant, and acid- and bile-salt-resistant properties, and can colonize the intestines. Furthermore, Lactobacillus vaginis 244 can enhance the resistance of piglets to PEDV infection, promote piglet growth, and alleviate clinical symptoms caused by PEDV infection. The Lactobacillus vaginis 244 provided by this invention offers a novel intervention target and control strategy for PEDV infection.

This invention provides a rumen methane inhibitor and its application, belonging to the field of ruminant farming. The active ingredients of the rumen methane inhibitor of this invention include: *Lactobacillus reuteri* inoculum, *Lactobacillus gasseri* inoculum, *Lactobacillus casei* inoculum, amylase, phytase, xylanase, cellulase, and β-glucanase. The rumen methane inhibitor can effectively regulate the intestinal microbiota of dairy cows, promote the decomposition of fibrous material in the rumen, optimize the rumen fermentation environment, thereby controlling rumen function, reducing methane production, and improving the productivity of ruminants. The rumen methane inhibitor is safe and environmentally friendly, which is conducive to its application in ruminant farming, agriculture, and other fields, and has good practicality.

The application discloses a use of a larazotide polypeptide in preparation of a drug for relieving adriamycin cardiotoxicity. In-vivo experimental results show that the larazotide can effectively relieve the toxic effect of a chemotherapeutic drug adriamycin on the heart, relieve myocardial enzyme spectrum increase, enhance left ventricular diastolic capacity and cardiac ejection fraction by improving body and heart immune cell homeostasis and reducing myocardial tissue cell apoptosis, thereby reducing the toxic side effect of the chemotherapeutic drug adriamycin, and improving intestinal barrier function damage caused by adriamycin chemotherapy. The application overcomes the defects of current clinical drug limitations of Dox and existing chemotherapeutic heart protection drugs, and solves the prevention and treatment problems of heart toxicity and intestinal side effects induced in Dox chemotherapy.

This invention discloses the application of emodin in the preparation of products that inhibit T cell exhaustion. In vitro screening revealed that emodin significantly inhibits T cell exhaustion. Mechanistic studies showed that emodin does not affect Granzyme B secretion, slightly inhibits the secretion level of the cytokine IFN-γ, and significantly reduces the accumulation of protein aggregates within T cells by inhibiting the AKT phosphorylation signaling pathway, thus maintaining cellular protein homeostasis and inhibiting T cell exhaustion. Animal experiments also confirmed that T cells treated with emodin significantly inhibited melanoma growth after adoptive infusion. Therefore, this invention provides the application of emodin in the preparation of products that inhibit T cell exhaustion, further offering a new small-molecule metabolic intervention strategy for improving the efficacy of immunotherapy for solid tumors.

This invention belongs to the field of organic chemistry, specifically providing a class of compounds that can be selectively activated by hypochlorous acid to release hydroxyl groups, along with their preparation methods and applications. These compounds, triggered by HOCl, can efficiently release target molecules containing hydroxyl groups, enabling corresponding treatment, intervention, or functional execution. Simultaneously, these compounds can generate detectable signals such as fluorescence while releasing the charge, allowing for in-situ / real-time monitoring of HOCl levels and the release process in lesion areas, providing a basis for disease assessment and efficacy tracking. These compounds remain relatively inert in normal tissues or when HOCl is at physiological levels, reducing disturbance to HOCl in normal areas and helping to maintain overall HOCl homeostasis and basic immune defense functions. This invention develops a class of compounds that can rapidly respond to hypochlorous acid, release hydroxyl-containing drugs, and monitor disease treatment.